In order to receive the certificate of participation, you are required to fill out the registration form.

Registration link

Thursday, October 23rd, 2025

02:30 PM (GMT)

06:00 PM (Tehran Time)

Join Zoom Meeting:

https://us06web.zoom.us/j/ 87138509357

Meeting ID: 871 3850 9357

Passcode: TUMS

Dr. Naveen Pemmaraju

Professor, Leukemia Department, The University of
Texas, MD Anderson Cancer Center, USA

Naveen Pemmaraju, MD is Professor in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, Texas. He is the inaugural Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program at MDACC and additionally serves as Executive Director for Cancer Medicine for the MDACC Cancer Network. Dr Pemmaraju is a world-leading clinical researcher and world-renowned speaker in the area of rare myeloid malignancies including BPDCN, MPN, and AML and has served as lead national/international PI on numerous key clinical trials in the field. Dr Pemmaraju’s leadership led to the approval of the first targeted therapy specifically approved in BPDCN in December 2018 (CD123-targeted therapy, tagraxofusp, Pemmaraju et al NEJM April 2019). He has authored/co-authored over 430+ papers in the medical literature and is currently the lead PI for 2 separate DOD grants. In addition, Dr Pemmaraju is a well-regarded clinician and highly sought after medical educator, having been awarded the Gerald P. Bodey Excellence in Teaching Award at MDACC in 2020, the MPN Hero Award in 2022, the Faculty Educator of the Year in 2023 for MDACC and the MDACC Community Outreach Faculty Excellence Award in 2023.

Dr. Sohrab Aghabeigi

Assistant Professor, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Iran

(Moderator)

Dr. Marjan Yaghmaie

Professor, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Head of Leading House for Iran-North America Academic Partnerships, Tehran University of Medical Sciences, Iran

(Facilitator)